Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation ...
Prostate cancer is the most commonly diagnosed cancer in males in 118 of 185 countries, but it's the leading cause of death ...
A new paper in the Journal of the National Cancer Institute indicates that patients may benefit if doctors stop calling ...
Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...
New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...
James Ware unfortunately fell into the statistic that one in six African American men will be diagnosed in their lifetime. He ...
HOUSTON — September is Prostate Cancer Awareness Month. One in eight men will be diagnosed during their lifetime, and it's ...
Research shows 69 per cent of Black adults are unaware that Black men face a two-fold increased risk of developing prostate ...